Citations

Clear

3057 citation(s) found for "Cd, Johnson".

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
Mascarenhas, John , Migliaccio, Anna Ritá , Kosiorek, Heidi , Bhave, Rupali , Palmer, Jeanne , Mesa, Ruben A. , Rampal, Raajit K. , Gerds, Aaron T. , Yacoub, Abdulraheem , Pettit, Kristen , Kremyanskaya, Marina , Gonzalez, Agapito , Fabris, Frank , Johnson, Kathryn , Dougherty, Mikaela , Domenico, Dylan , Farnoud, Noushin , Weinberg, Rona Singer , Kong, Amy , Najfeld, Vesna , Arciprete, Francesca , Falchi, Mario , Salama, Mohamed E. , Mead‐Harvey, Carolyn , Dueck, Amylou C. , Varricchio, Lilian , Dueck, A. C. , Kuykendall, Andrew , Mesa, Ruben , Rampal, Raajit K , Gerds, Aaron T , Yacoub, Abdulraheem , Pettit, Kristen , Talpaz, Moshe , Komrokji, Rami S , Kremyanskaya, Marina , Gonzalez, Agapito , Fabris, Frank , Johnson, Kathryn , Dougherty, Mikaela , McGovern, Erin , Arango Ossa, Juan E , Domenico, Dylan , Farnoud, Noushin , Weinberg, Rona Singer , Kong, Amy , Najfeld, Vesna , Vannucchi, Alessandro M , Arciprete, Francesca , Zingariello, Maria , Falchi, Mario , Salama, Mohamed E , Mead-Harvey, Carolyn , Varricchio, Lilian , Hoffman, Ronald , Mascarenhas, John , Kosiorek, Heidi E , Talpaz, Moshe , Komrokji, Rami S. , McGovern, Erin , Ossa, Juan Arango , Vannucchi, Alessandro M.

Mayo Clinic

Clinical Cancer Research | July 13, 2023 | Volume: 29 | Issue: 18 | Pages: 3622-3632

10.1158/1078-0432.ccr-23-0276 | PMID 37439808 Get It

Abstract Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the disease course and frequently lead to thrombocytopenia. TGFβ, a pleiotropic cytokine elaborated by the MF clone, negatively regulates normal hematopoiesis, downregulates antitumor immunity, and promotes bone marrow fibrosis. Our group previously showed that AVID200, a potent and selective TGFβ 1/3 trap, reduced TGFβ1-induced proliferation of human mesenchymal stromal cells, phosphorylation of SMAD2, and collagen expression. Moreover, treatment of MF mononuclear cells with AVID200 led to increased numbers of progenitor cells (PC) with wild-type JAK2 rather than JAK2V617F. Patients and Methods: We conducted an investigator-initiated, multicenter, phase Ib trial of AVID200 monotherapy in 21 patients with advanced MF. Results: No dose-limiting toxicity was identified at the three dose levels tested, and grade 3/4 anemia and thrombocytopenia occurred in 28.6% and 19.0% of treated patients, respectively. After six cycles of therapy, two patients attained a clinical benefit by IWG-MRT criteria. Spleen and symptom benefits were observed across treatment cycles. Unlike other MF-directed therapies, increases in platelet counts were noted in 81% of treated patients with three patients achieving normalization. Treatment with AVID200 resulted in potent suppression of plasma TGFβ1 levels and pSMAD2 in MF cells. Conclusions: AVID200 is a well-tolerated, rational, therapeutic agent for the treatment of patients with MF and should be evaluated further in patients with thrombocytopenic MF in combination with agents that target aberrant MF intracellular signaling pathways.
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real‐world patient data repository
Farber, Harrison W. , Chakinala, Murali M. , Cho, Michelle, Frantz, Robert P. , Frick, Andrew , Lancaster, Lisa , Milligan, Scott , Oudiz, Ronald J. , Panjabi, Sumeet , Tsang, Yuen, Nathan, Steven D. , Frantz, Robert P , Oudiz, Ronald

Mayo Clinic

Pulmonary Circulation | July 7, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1002/pul2.12258 | PMID 37427090 Get It

AbstractPulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository (TRIO CIPDR), is an innovative US repository capturing data on contemporary patients diagnosed with pulmonary hypertension and receiving US Food and Drug Administration‐approved PAH therapies. This repository uniquely combines clinical data from electronic medical records with the ability to track drug‐prescription and drug‐dispensing characteristics, and includes 946 adult patients with PAH (data collected January 2019 to December 2020) enrolled from nine representative US specialist tertiary care centers. Potentially eligible patients were identified based on dispensing data from specialty pharmacies. Hemodynamic and clinical data, as well as dispensing information on prescribed PAH medications, were provided by tertiary centers. At enrollment, 75% of patients were female, 67% were White, median age at PAH diagnosis was 53 years (median time from diagnosis to enrollment was 5 years), and 37% were obese. Comorbidity profiles were as expected for a PAH population, although the proportion with atrial fibrillation (34%) was higher than expected. Overall, 38% of patients had idiopathic PAH and 30% had connective tissue disease‐related PAH. Among 917 patients receiving PAH‐specific therapy, 40% were on monotherapy, 43% on dual therapy, and 17% on triple therapy. Longitudinal data from this repository will allow tracking of the PAH treatment journey in relation to clinical characteristics and outcomes.
Machine learning can accurately predict risk factors for all‐cause reoperation after ACLR: creating a clinical tool to improve patient counseling and outcomes
Johnson, Quinn J. , Jabal, Mohamed Sobhi , Arguello, Alexandra M. , Jurgensmeier, Kevin , Levy, Bruce A. , Krych, Aaron J. , Jabal, Mohamed S, Krych, Aaron J , Jurgensmeier, Kevin , Lu, Yining , Camp, Christopher L.

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | July 6, 2023 | Volume: 31 | Issue: 10 | Pages: 4099-4108

10.1007/s00167-023-07497-7 | PMID 37414947 Get It

AbstractPurposeIdentifying predictive factors for all‐cause reoperation after anterior cruciate ligament reconstruction could inform clinical decision making and improve risk mitigation. The primary purposes of this study are to (1) determine the incidence of all‐cause reoperation after anterior cruciate ligament reconstruction, (2) identify predictors of reoperation after anterior cruciate ligament reconstruction using machine learning methodology, and (3) compare the predictive capacity of the machine learning methods to that of traditional logistic regression.MethodsA longitudinal geographical database was utilized to identify patients with a diagnosis of new anterior cruciate ligament injury. Eight machine learning models were appraised on their ability to predict all‐cause reoperation after anterior cruciate ligament reconstruction. Model performance was evaluated via area under the receiver operating characteristics curve. To explore modeling interpretability and radiomic feature influence on the predictions, we utilized a game‐theory‐based method through SHapley Additive exPlanations.ResultsA total of 1400 patients underwent anterior cruciate ligament reconstruction with a mean postoperative follow‐up of 9 years. Two‐hundred and eighteen (16%) patients experienced a reoperation after anterior cruciate ligament reconstruction, of which 6% of these were revision ACL reconstruction. SHapley Additive exPlanations plots identified the following risk factors as predictive for all‐cause reoperation: diagnosis of systemic inflammatory disease, distal tear location, concomitant medial collateral ligament repair, higher visual analog scale pain score prior to surgery, hamstring autograft, tibial fixation via radial expansion device, younger age at initial injury, and concomitant meniscal repair. Pertinent negatives, when compared to previous studies, included sex and timing of surgery. XGBoost was the best‐performing model (area under the receiver operating characteristics curve of 0.77) and outperformed logistic regression in this regard.ConclusionsAll‐cause reoperation after anterior cruciate ligament reconstruction occurred at a rate of 16%. Machine learning models outperformed traditional statistics and identified diagnosis of systemic inflammatory disease, distal tear location, concomitant medial collateral ligament repair, higher visual analog scale pain score prior to surgery, hamstring autograft, tibial fixation via radial expansion device, younger age at initial injury, and concomitant meniscal repair as predictive risk factors for reoperation. Pertinent negatives, when compared to previous studies, included sex and timing of surgery. These models will allow surgeons to tabulate individualized risk for future reoperation for patients undergoing anterior cruciate ligament reconstruction.Level of evidenceIII.
Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients
Aibaidula, Abudumijiti, Fain, Cori E. , Garcia, Luz Cumba, Wier, Annelise, Bouchal, Samantha M. , Jung, M. Katherine , Johnson, Aaron J. , Parney, Ian F. , Aibaidula, Abudumijiti Zack, Jung, Mi-Yeon, Parney, Ian F , Bouchal, Samantha M , Bauman, Megan M. J. , Sarkaria, Jann N. , Johnson, Aaron J.

Mayo Clinic

Neuro-Oncology Advances | July 5, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad082 | PMID 37638345 Get It

Abstract Background Glioblastoma (GBM) is the most common malignant brain tumor and has a poor prognosis. Imaging findings at diagnosis and in response to treatment are nonspecific. Developing noninvasive assays to augment imaging would be helpful. Plasma extracellular vesicles (EVs) are a promising biomarker source for this. Here, we develop spectral flow cytometry techniques that demonstrate differences in bulk plasma EV phenotype between GBM patients and normal donors that could serve as the basis of a liquid biopsy. Methods Plasma EVs were stained for EV-associated tetraspanins (CD9/CD63/CD81), markers indicating cell of origin (CD11b/CD31/CD41a/CD45), and actin/phalloidin (to exclude cell debris). EVs were analyzed using spectral flow cytometry. Multiparametric analysis using t-distributed stochastic neighbor embedding (t-SNE) and self-organizing maps on flow cytometry data (FlowSOM) was performed comparing GBM and normal donor (ND) plasma EVs. Results Size exclusion chromatography plus spectral-based flow cytometer threshold settings enriched plasma EVs while minimizing background noise. GBM patients had increased CD9+, CD63+, CD81+, and myeloid-derived (CD11b+) EVs. Multiparametric analysis demonstrated distinct surface marker expression profiles in GBM plasma EVs compared to ND EVs. Fifteen plasma EV sub-populations differing in size and surface marker expression were identified, six enriched in GBM patients and two in normal donors. Conclusions Multiparametric analysis demonstrates that GBM patients have a distinct nonneoplastic plasma EV phenotype compared to ND. This simple rapid analysis can be performed without purifying tumor EVs and may serve as the basis of a liquid biopsy.
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data
Silvert, Eli , Hester, Laura , Ramudu, Eshwan , Kranenburg, Britte, Muchtar, Eli , Khaled, Samer K. , Tran, NamPhuong, Khan, Najat, Muchtar, E , Gertz, Morie A , Dispenzieri, Angela , Hester, Laura , Pawlowski, Colin , Buadi, Francis K. , Soundararajan, Venky , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 5, 2023 | Volume: 98 | Issue: 9 | Pages: No page available

10.1002/ajh.27019 | PMID 37403432 Get It

Association of the CHEK2 c. 1100delC variant, radiotherapy, and systemic treatment with contralateral b
Morra, Anna , Schreurs, Maartje A. C. , Andrulis, Irene L. , Anton‐Culver, Hoda , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Graßmann, Felix , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Hopper, John L. , Houlston, Richard S. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lindblom, Annika , Mannermaa, Arto, Mavroudis, Dimitrios, Muranen, Taru , Nevelsteen, Ines, Neven, Patrick , Newman, William G. , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Peterlongo, Paolo , Phillips, Kelly‐Anne , Plaseska‐Karanfilska, Dijana , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Pharoah, Paul D.P. , Adank, Muriel A. , Hooning, Maartje J. , Howell, Anthony , Ramus, Susan J. , Bojesen, Stig E. , Eccles, Diana , Cummings, Margaret C. , Loi, Sherene , Lambrechts, Diether , Howell, Sacha J. , Bojesen, Stig E , Dörk, Thilo , Figueroa, Jonine D , Gabrielson, Marike , Gago-Dominguez, Manuela , García-Sáenz, José A , Hahnen, Eric , Hartikainen, Jaana M , Jernström, Helena , John, Esther M , Lambrechts, Diether , Muranen, Taru A , Nevanlinna, H , Patel, Alpa V , Pylkäs, Katri , Rashid, Muhammad U , Hooning, Maartje J. , Lambrechts, Diether , Peterlongo, Paolo , Ramus, Susan J , Pharoah, Paul D P , Eccles, Diana , Houlston, Richard S , Anton-Culver, Hoda , Evans, D Gareth , Jones, Michael E , Newman, William G , Romero, Atocha , García-Closas, Montserrat , Kurian, Allison W , Loi, Sherene , Bojesen, Stig E , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Augustinsson, Annelie , Behrens, Sabine , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Collaborators, NBCS, Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Dennis, Joe , Devilee, Peter , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Hartikainen, Jaana M. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Jakubowska, Anna , Jernström, Helena , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mannermaa, Arto, Mulligan, Anna Marie , Nevanlinna, Heli , Olshan, Andrew F. , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Saloustros, Emmanouil , Scott, Christopher G. , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

Cancer Medicine | July 4, 2023 | Volume: 12 | Issue: 15 | Pages: 16142-16162

10.1002/cam4.6272 | PMID 37401034 Get It

Abstract Background Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers. Aim To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Methods Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. Results There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)]. Conclusion Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
Optimizing single cell proteomics using trapped ion mobility spectrometry for label-free experiments
Mun, Dong‐Gi , Bhat, Firdous Ahmad , Ding, Husheng, Natesampillai, Sekar, Johnson, Kenneth L. , Pandey, Akhilesh , Bhat, Firdous A., Pandey, Akhilesh , Mun, Dong-Gi , Madden, Benjamin J. , Badley, Andrew D. , Kelly, Ryan T

Mayo Clinic

The Analyst | July 3, 2023 | Volume: 148 | Issue: 15 | Pages: 3466-3475

10.1039/d3an00080j | PMID 37395315 Get It

We present optimized settings for ramp times and ion mobility range in trapped ion mobility spectrometry experiments involving single cell analysis.
The SERPINA5 coding variant E228Q does not contribute to clinicopathologic characteristics in Alzheimer’s disease: A cross-sectional study
Lincoln, Sarah, Baker, Matt , Tamvaka, Nikoleta, Sirmans, Tiffany N. Hicks , Moloney, Christina M. , Helminger, Jacqueline, Hinkle, Kelly M., Cabrera-Rodriguez, Janisse, Wickland, Daniel P. , Reddy, Joseph S. , Younkin, Steven G. , Carrasquillo, Minerva M. , Duara, Ranjan , Graff‐Radford, Neill R. , Pottier, Cyril , Ertekin‐Taner, Nilüfer , Ross, Owen A. , Rademakers, Rosa , Matchett, Billie J. , Lincoln, Sarah J, Labuzan, Sydney A. , Hicks Sirmans, Tiffany N, Murray, Melissa E , Ross, Owen A , Pottier, Cyril , Johnson, Patrick W. , Heckman, Michael G. , Carrasquillo, Minerva M. , Duara, Ranjan , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Medicine | June 16, 2023 | Volume: 102 | Issue: 24 | Pages: e34017

10.1097/md.0000000000034017 | PMID 37327267 Get It

We previously demonstrated that increased expression of the SERPINA5 gene is associated with hippocampal vulnerability in Alzheimer’s disease (AD) brains. SERPINA5 was further demonstrated to be a novel tau-binding partner that colocalizes within neurofibrillary tangles. Our goal was to determine whether genetic variants in the SERPINA5 gene contributed to clinicopathologic phenotypes in AD. To screen for SERPINA5 variants, we sequenced 103 autopsy-confirmed young-onset AD cases with a positive family history of cognitive decline. To further assess the frequency of a rare missense variant, SERPINA5 p.E228Q, we screened an additional 1114 neuropathologically diagnosed AD cases. To provide neuropathologic context in AD, we immunohistochemically evaluated SERPINA5 and tau in a SERPINA5 p.E228Q variant carrier and a matched noncarrier. In the initial SERPINA5 screen, we observed 1 individual with a rare missense variant (rs140138746) that resulted in an amino acid change (p.E228Q). In our AD validation cohort, we identified an additional 5 carriers of this variant, resulting in an allelic frequency of 0.0021. There was no significant difference between SERPINA5 p.E228Q carriers and noncarriers in terms of demographic or clinicopathologic characteristics. Although not significant, on average SERPINA5 p.E228Q carriers were 5 years younger at age of disease onset than noncarriers (median: 66 [60–73] vs 71 [63–77] years, P = .351). In addition, SERPINA5 p.E228Q carriers exhibited a longer disease duration than noncarriers that approached significance (median: 12 [10–15]) vs 9 [6–12] years, P = .079). More severe neuronal loss was observed in the locus coeruleus, hippocampus, and amygdala of the SERPINA5 p.E228Q carrier compared to noncarrier, although no significant difference in SERPINA5-immunopositive lesions was observed. Throughout the AD brain in either carrier or noncarrier, areas with early pretangle pathology or burnt-out ghost tangle accumulation did not reveal SERPINA5-immunopositive neurons. Mature tangles and newly formed ghost tangles appeared to correspond well with SERPINA5-immunopositive tangle-bearing neurons. SERPINA5 gene expression was previously associated with disease phenotype; however, our findings suggest that SERPINA5 genetic variants may not be a contributing factor to clinicopathologic differences in AD. SERPINA5-immunopositive neurons appear to undergo a pathologic process that corresponded with specific levels of tangle maturity.
Management of Partial-Thickness Tears of the Distal Bicep Tendon: Evaluation of 111 Patients With 10-Year Follow-up
Till, Sara E., Wilbur, Ryan R. , Song, Bryant M. , Reinholz, Anna K., Johnson, Adam C. , Sanchez-Sotelo, Joaquin, Tagliero, Adam J. , Sánchez‐Sotelo, Joaquín , Barlow, Jonathan D. , Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 16, 2023 | Volume: 11 | Issue: 6 | Pages: No page available

10.1177/23259671231169202 | PMID 37342555 Get It

Background: There is a paucity of research on the management of partial-thickness tears of the distal bicep tendon, and even less is known about the long-term outcomes of this condition. Purpose: To identify patients with partial-thickness distal bicep tendon tears and determine (1) patient characteristics and treatment strategies, (2) long-term outcomes, and (3) any identifiable risk factors for progression to surgery or complete tear. Study Design: Case-control study; Level of evidence, 3. Methods: A fellowship-trained musculoskeletal radiologist identified patients diagnosed with a partial-thickness distal bicep tendon tear on magnetic resonance imaging between 1996 and 2016. Medical records were reviewed to confirm the diagnosis and record study details. Multivariate logistic regression models were created using baseline characteristics, injury details, and physical examination findings to predict operative intervention. Results: In total, 111 patients met inclusion criteria (54 treated operatively, 57 treated nonoperatively), with 53% of tears in the nondominant arm and a mean follow-up time after surgery of 9.7 ± 6.5 years. Only 5% of patients progressed to full-thickness tears during the study period, at a mean of 35 months after the initial diagnosis. Patients who were nonoperatively treated were less likely to miss time from work (12% vs 61%; P < .001) and missed fewer days (30 vs 97 days; P < .016) than those treated surgically. Multivariate regression analyses demonstrated increased risk of progression to surgery with older age at initial consult (unit odds ratio [OR], 1.1), tenderness to palpation (OR, 7.5), and supination weakness (OR, 24.8). Supination weakness at initial consult was a statistically significant predictor for surgical intervention (OR, 24.8; P = .001). Conclusion: Clinical outcomes were favorable for patients regardless of treatment strategy. Approximately 50% of patients were treated surgically; patients with supination weakness were 24 times more likely to undergo surgery than those without. Progression to full-thickness tear was a relatively uncommon reason for surgical intervention, with only 5% of patients progressing to full-thickness tears during the study period and the majority occurring within 3 months of initial diagnosis.
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Fa’ak, Faisal , Buni, Maryam, Falohun, Adewunmi, Song, Juhee , Trinh, Van Anh, Tahon, Nourel Hoda , Elsayes, Khaled M. , Ludford, Kaysia , Montazari, Emma J., Chernis, Julia , Dimitrova, Maya , Sandigursky, Sabina, Sparks, Jeffrey A. , Abu-Shawer, Osama , Rahma, Osama E. , Thanarajasingam, Uma , Zeman, Ashley M., Talukder, Rafee , Chung, Sarah H. , Grivas, Petros , Daher, May , Abudayyeh, Ala , Osman, Iman , Suarez‐Almazor, María E. , Abdel‐Wahab, Noha , Diab, Adi , Grivas, Petros , Weber, Jeffrey , Diab, Adi , Sparks, Jeffrey A , Lu, Huifang , Johnson, Daniel Hartman , Zobniw, Chrystia M. , Awiwi, Muhammad O. , Singh, Namrata , Weber, Jeffrey S. , Tayar, Jean H.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 16, 2023 | Volume: 11 | Issue: 6 | Pages: e006814

10.1136/jitc-2023-006814 | PMID 37328287 Get It

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs. Methods We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R. Our objectives were to assess the improvement of irAEs as well as the overall tumor response rate (ORR) before and after anti-IL-6R treatment. Results We identified a total of 92 patients who received therapeutic anti-IL-6R antibodies (tocilizumab or sarilumab). Median age was 61 years, 63% were men, 69% received anti-programmed cell death protein-1 (PD-1) antibodies alone, and 26% patients were treated with the combination of anti-cytotoxic T lymphocyte antigen-4 and anti-PD-1 antibodies. Cancer types were primarily melanoma (46%), genitourinary cancer (35%), and lung cancer (8%). Indications for using anti-IL-6R antibodies included inflammatory arthritis (73%), hepatitis/cholangitis (7%), myositis/myocarditis/myasthenia gravis (5%), polymyalgia rheumatica (4%), and one patient each with autoimmune scleroderma, nephritis, colitis, pneumonitis and central nervous system vasculitis. Notably, 88% of patients had received corticosteroids, and 36% received other disease-modifying antirheumatic drugs (DMARDs) as first-line therapies, but without adequate improvement. After initiation of anti-IL-6R (as first-line or post-corticosteroids and DMARDs), 73% of patients showed resolution or change to ≤grade 1 of irAEs after a median of 2.0 months from initiation of anti-IL-6R therapy. Six patients (7%) stopped anti-IL-6R due to adverse events. Of 70 evaluable patients by RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria; the ORR was 66% prior versus 66% after anti-IL-6R (95% CI, 54% to 77%), with 8% higher complete response rate. Of 34 evaluable patients with melanoma, the ORR was 56% prior and increased to 68% after anti-IL-6R (p=0.04). Conclusion Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs ( NCT04940299 , NCT03999749 ).